<!DOCTYPE html>

<html lang="en">
<head>
	<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
	<meta name="viewport" content="width=device-width, initial-scale=1">
	<title></title>
	<link rel="stylesheet" href="css/dh.css" type="text/css" />
	<link rel="stylesheet" href="css/animate.css" type="text/css" />
	<script type="text/javascript" src="js/base.js"></script>
	<script type="text/javascript" src="js/Common.js"></script>
    <script type="text/javascript" charset="utf-8">
		

		ANIMATION = [
			
		   ];
		
	</script>
    
    <script type="text/javascript">
			
			
		function touching() {
			var touchBtn = document.getElementById("touch");
			var panel1 = document.getElementById("panel1");
			var content = document.getElementById("content");
			var temp1 = document.getElementById("panel1");
			
			if (panel1.className!='active') {
				panel1.setAttribute('class','active');
				temp1.style.zIndex = '100'
				makecall('TrackPopup',Array('DHHS HIV Guidelines'));
			}
			else if (panel1.className='active') {
				panel1.setAttribute('class','deactive');
				}
			};
	</script>
    

</head>

<body class="slide-1">

<div id="content" onclick="touching()">
<div class="collage"></div>

<header>
Factors to consider when selecting an initial regimen

</header>

<div class="logo"></div>


<section >

	<div class="guidelines" ><img src="images/ps-02-ctaicon.png" alt="tap here" style="position:relative; top:307px; left:234px;" /></div>

	<div class="chartbk" >
    		
            <div id="panel1">
            	<h2>DHHS HIV Guidelines for ARV-na√Øve adults<sup>2</sup></h2>
				<div class="rippedpage">
                
                    Regimen selection should be individualized and should be based on a number of factors, including: 
                    <ul>
                    <li>comorbid conditions (e.g., cardiovascular disease, chemical dependency, liver disease, psychiatric<br>
                    disease, renal diseases, or tuberculosis);</li>
                    <li>potential adverse drug effects;</li>
                    <li>potential drug interactions with other medications;</li>
                    <li>pregnancy or pregnancy potential; </li> 
                    <li>results of genotypic drug-resistance testing;</li>
                    <li>gender and pretreatment CD4 count if considering nevirapine (NVP);</li>
                    <li>HLA-B*5701 testing if considering abacavir (ABC); </li>
                    <li>coreceptor tropism assay if considering maraviroc (MVC);</li>
                    <li>patient adherence potential; </li>
					<li>convenience (e.g., pill burden, dosing frequency, and food and
                    fluid considerations). </li> 
                    </ul>   
                </div>


            </div>
       
    </div>

</section>



<footer>Please click buttons above for Indication and Important Safety Information about KALETRA.</footer>


</div>
</body>
</html>